{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T12:13:44Z","timestamp":1767183224244,"version":"3.40.4"},"reference-count":58,"publisher":"Oxford University Press (OUP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,2,15]]},"DOI":"10.2146\/ajhp130506","type":"journal-article","created":{"date-parts":[[2014,1,30]],"date-time":"2014-01-30T20:39:19Z","timestamp":1391114359000},"page":"279-288","source":"Crossref","is-referenced-by-count":9,"title":["Omacetaxine for treatment-resistant or treatment-intolerant adult chronic myeloid leukemia"],"prefix":"10.1093","volume":"71","author":[{"given":"Clement","family":"Chung","sequence":"first","affiliation":[{"name":"Lyndon B. Johnson General Hospital, Harris Health System, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"2019041210503855700_b1-0710279","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0002-9343(77)90124-3","article-title":"Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet, and monocyte\/macrophage","volume":"63","author":"Fialkow","year":"1977","journal-title":"Am J Med"},{"key":"2019041210503855700_b2-0710279","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"The biology of chronic myeloid leukemia","volume":"341","author":"Faderl","year":"1999","journal-title":"N Engl J Med"},{"key":"2019041210503855700_b3-0710279","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/sj.onc.1209756","article-title":"Fusion tyrosine kinase: a result and cause of genomic instability","volume":"26","author":"Penserga","year":"2007","journal-title":"Oncogene"},{"key":"2019041210503855700_b4-0710279","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"key":"2019041210503855700_b5-0710279","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","article-title":"Molecular biology of BCR-ABL-positive chronic myeloid leukemia","volume":"113","author":"Quintas-Cardama","year":"2009","journal-title":"Blood"},{"key":"2019041210503855700_b6-0710279","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.beha.2009.07.007","article-title":"Epidemiology of chronic myeloid leukaemia (CML)","volume":"22","author":"Rohrbacher","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"key":"2019041210503855700_b7-0710279","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.3109\/10428194.2012.745525","article-title":"Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009","volume":"54","author":"Chen","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"2019041210503855700_b8-0710279","unstructured":"National Cancer Institute. SEER (Surveillance, Epidemiology and End Results) statistics. http:\/\/seer.cancer.gov (accessed 2013 Aug 3)."},{"key":"2019041210503855700_b9-0710279","first-page":"2433","article-title":"Chronic myelogenous leukemia","author":"Kantarjian","year":"2001"},{"key":"2019041210503855700_b10-0710279","doi-asserted-by":"crossref","first-page":"4368","DOI":"10.1182\/blood.V84.12.4368.bloodjournal84124368","article-title":"Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia","volume":"84","author":"Clift","year":"1994","journal-title":"Blood"},{"key":"2019041210503855700_b11-0710279","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1056\/NEJM199303043280901","article-title":"Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program","volume":"328","author":"Kernan","year":"1993","journal-title":"N Engl J Med"},{"year":"2012","key":"2019041210503855700_b12-0710279"},{"key":"2019041210503855700_b13-0710279","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","article-title":"The World Health Organization (WHO) classification of the myeloid neoplasm","volume":"100","author":"Vardiman","year":"2002","journal-title":"Blood"},{"key":"2019041210503855700_b14-0710279","unstructured":"National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology: chronic myelogenous leukemia. v.4.2013. www.nccn.org (accessed 2013 Jul 20)."},{"key":"2019041210503855700_b15-0710279","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3324\/haematol.12588","article-title":"Monitoring treatment of CML","volume":"93","author":"Baccarani","year":"2008","journal-title":"Haematologica"},{"key":"2019041210503855700_b16-0710279","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1182\/blood-2007-03-080838","article-title":"Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors","volume":"110","author":"Cortes","year":"2007","journal-title":"Blood"},{"key":"2019041210503855700_b17-0710279","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"key":"2019041210503855700_b18-0710279","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"key":"2019041210503855700_b19-0710279","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"2019041210503855700_b20-0710279","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"2019041210503855700_b21-0710279","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.clml.2013.03.017","article-title":"Homoharringtonine\/omacetaxine mepesuccinate: the long and winding road to Food and Drug Administration approval","volume":"13","author":"Kantarjian","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2019041210503855700_b22-0710279","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0026-895X(25)10662-7","article-title":"Harringtonine, an inhibitor of initiation of protein biosynthesis","volume":"11","author":"Huang","year":"1975","journal-title":"Mol Pharmacol"},{"key":"2019041210503855700_b23-0710279","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jmb.2009.04.005","article-title":"U2504 determines the species specificity of the A-site cleft antibiotics: the structures of tiamulin, homoharringtonine, and bruceantin bound to the ribosome","volume":"389","author":"Gurel","year":"2009","journal-title":"J Mol Biol"},{"key":"2019041210503855700_b24-0710279","first-page":"555a","article-title":"Homoharringtonine induces apoptosis in chronic myelogenous leukemia","volume":"82","author":"O\u2019Brien","year":"1993","journal-title":"Blood"},{"key":"2019041210503855700_b25-0710279","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/BF00258117","article-title":"Biologic and pharmacologic effects of harringtonine on human leukemia-lymphoma cells","volume":"14","author":"Takemura","year":"1985","journal-title":"Cancer Chemother Pharmacol"},{"key":"2019041210503855700_b26-0710279","first-page":"69","article-title":"Influence of harringtonine on human leukemia cell differentiation","volume":"37","author":"Kuliczkowski","year":"1989","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"2019041210503855700_b27-0710279","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/sj.leu.2400608","article-title":"Effects of homoharringtonine alone and in combination with alpha interferon and cytosine arabinoside on \u2018in vitro\u2019 growth and induction of apoptosis in chronic myeloid leukemia and normal hematopoietic progenitors","volume":"11","author":"Visani","year":"1997","journal-title":"Leukemia"},{"key":"2019041210503855700_b28-0710279","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1182\/blood.V114.22.644.644","article-title":"Safety and efficacy of subcutaneous-administered omacetaxine mepesuccinate in imatinib-resistant chronic myeloid leukemia (CML) patients who harbor the Bcr-Abl T315I mutation\u2014 results of an ongoing multicenter phase 2\/3 study","volume":"114","author":"Cortes-Franco","year":"2009","journal-title":"Blood"},{"key":"2019041210503855700_b29-0710279","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1182\/blood.V114.22.861.861","article-title":"Safety and efficacy of subcutaneous-administered omacetaxine mepesuccinate in chronic myeloid leukemia (CML) patients who are resistant or intolerant to two or more tyrosine kinase inhibitors\u2014results of a multicenter phase 2\/3 study","volume":"114","author":"Cortes-Franco","year":"2009","journal-title":"Blood"},{"key":"2019041210503855700_b30-0710279","first-page":"175","article-title":"Experimental studies on the toxicity of harringtonine and homoharringtonine","volume":"92","author":"Zhang","year":"1979","journal-title":"Chin Med J (Engl)"},{"key":"2019041210503855700_b31-0710279","first-page":"1403","article-title":"Clinical pharmacology of homoharringtonine","volume":"70","author":"Savaraj","year":"1986","journal-title":"Cancer Treat Rep"},{"key":"2019041210503855700_b32-0710279","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/BF00162769","article-title":"Central nervous system (CNS) penetration of homoharringtonine (HHT)","volume":"5","author":"Savaraj","year":"1987","journal-title":"J Neurooncol"},{"key":"2019041210503855700_b33-0710279","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/sj.bjc.6603265","article-title":"A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukemia","volume":"95","author":"Levy","year":"2006","journal-title":"Br J Cancer"},{"key":"2019041210503855700_b34-0710279","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00280-012-1963-2","article-title":"Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors","volume":"71","author":"Nemunaitis","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"2019041210503855700_b35-0710279","first-page":"319","article-title":"Harringtonine in acute leukemia. Clinical analysis of 31 cases","volume":"3","author":"Hospital CPsLAt","year":"1977","journal-title":"Chin Med J (Engl)"},{"key":"2019041210503855700_b36-0710279","first-page":"2263","article-title":"Cephalotaxine esters in the treatment of acute leukemia. A preliminary clinical assessment","volume":"2","author":"Group","year":"1976","journal-title":"Chin Med J (Engl)"},{"key":"2019041210503855700_b37-0710279","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/cncr.22398","article-title":"Phase I\/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy","volume":"109","author":"Quintas-Cardama","year":"2007","journal-title":"Cancer"},{"key":"2019041210503855700_b38-0710279","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood.V86.9.3322.bloodjournal8693322","article-title":"Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase","volume":"86","author":"O\u2019Brien","year":"1995","journal-title":"Blood"},{"key":"2019041210503855700_b39-0710279","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1002\/cncr.10436","article-title":"Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia","volume":"94","author":"O\u2019Brien","year":"2002","journal-title":"Cancer"},{"key":"2019041210503855700_b40-0710279","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1002\/cncr.20975","article-title":"Phase I\/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib","volume":"103","author":"Marin","year":"2005","journal-title":"Cancer"},{"issue":"suppl 4","key":"2019041210503855700_b41-0710279","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.exphem.2007.01.023","article-title":"Optimizing therapy of chronic myeloid leukemia","volume":"35","author":"Deininger","year":"2007","journal-title":"Exp Hematol"},{"key":"2019041210503855700_b42-0710279","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s11864-013-0234-8","article-title":"Chronic myeloid leukemia: overview of new agents and comparative analysis","volume":"14","author":"Jain","year":"2013","journal-title":"Curr Treat Options Oncol"},{"key":"2019041210503855700_b43-0710279","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3324\/haematol.10822","article-title":"Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutation at residues 315 and 317 in the BCR-ABL kinase domain","volume":"92","author":"Soverini","year":"2007","journal-title":"Haematologica"},{"key":"2019041210503855700_b44-0710279","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2007-11-123950","article-title":"Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy","volume":"112","author":"Jabbour","year":"2008","journal-title":"Blood"},{"key":"2019041210503855700_b45-0710279","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1182\/blood-2012-03-415307","article-title":"Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic phase CML with T315I mutation","volume":"120","author":"Cortes","year":"2012","journal-title":"Blood"},{"issue":"suppl 15","key":"2019041210503855700_b46-0710279","article-title":"Subcutaneous omacetaxine mepesuccinate in patients with chronic phase (CP) or accelerated phase (AP) chronic myelogenous leukemia (CML) resistant\/ intolerant to two or three approved tyrosine-kinase inhibitors (TKIs)","volume":"30","author":"Nicolini","year":"2012","journal-title":"J Clin Oncol"},{"issue":"suppl 15","key":"2019041210503855700_b47-0710279","article-title":"Omacetaxine mepesuccinate in chronic-phase chronic myeloid leukemia (CML) in patients resistant, intolerant, or both to two or more tyrosine kinase inhibitors (TKIs)","volume":"30","author":"Akard","year":"2012","journal-title":"J Clin Oncol"},{"issue":"suppl 15","key":"2019041210503855700_b48-0710279","article-title":"Pooled safety analysis of omacetaxine mepesuccinate in patients with chronic myeloid leukemia (CML) resistant to tyrosine-kinase inhibitors (TKIs)","volume":"30","author":"Wetzler","year":"2012","journal-title":"J Clin Oncol"},{"key":"2019041210503855700_b49-0710279","unstructured":"Drug topics, omacetaxine mepesuccinate (Synribo). Red Book Online. Greenwood Village, CO: Thompson Micromedex. Available from www.micromedexsolutions.com (accessed 2013 Jul 29)."},{"key":"2019041210503855700_b50-0710279","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1182\/blood-2009-05-221531","article-title":"The use of nilotinib or dasatinib after failure of 2 prior tyrosine kinase inhibitors: long-term follow-up","volume":"114","author":"Garg","year":"2009","journal-title":"Blood"},{"key":"2019041210503855700_b51-0710279","first-page":"225","article-title":"Analysis of the therapeutic efficacy and prognostic factors of intensive chemotherapy in 91 patients with acute non-lymphocytic leukemia","volume":"29","author":"Bian","year":"1990","journal-title":"Chung Hua Nei Ko Tsa Chih"},{"key":"2019041210503855700_b52-0710279","first-page":"565","article-title":"High remission induction (traditional SinoWestern HOAP) regimen for acute nonlymphocytic leukemia","volume":"93","author":"Hematology Research Division and Hematology Section of the Children\u2019s Hospital, Suzhou Medical College","year":"1980","journal-title":"Chin Med J (Engl)"},{"key":"2019041210503855700_b53-0710279","first-page":"40","article-title":"Homoharringtonine in patients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia","volume":"10","author":"Feldman","year":"1996","journal-title":"Leukemia"},{"key":"2019041210503855700_b54-0710279","first-page":"319","article-title":"Clinical study of cephalotaxine ester in the treatment of acute non-lymphoid leukemia","volume":"6","author":"Shanghai Leukemia Research Cooperative Group","year":"1983","journal-title":"Shanghai Med J"},{"key":"2019041210503855700_b55-0710279","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1080\/00034983.1990.11812462","article-title":"Treatment of chloroquine-resistant malaria with esters of cephalotaxine: homoharringtonine","volume":"84","author":"Whaun","year":"1990","journal-title":"Ann Trop Med Parasitol"},{"key":"2019041210503855700_b56-0710279","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1007\/s10147-012-0453-1","article-title":"Homoharringtonine is an effective therapy for patients with polycythemia vera or essential thrombocythemia who have failed or were intolerant to hydroxycarbamide or interferon-a therapy","volume":"18","author":"Li","year":"2013","journal-title":"Int J Clin Oncol"},{"key":"2019041210503855700_b57-0710279","unstructured":"ClinicalTrials.gov. A phase II study of omacetaxine (OM) and low dose cytarabine (LDAC) in older patients with acute myelogenous leukemia (AML) and high-risk myelodysplastic syndrome (MDS). www.clinicaltrials.gov\/ct2\/show\/NCT01272245 (accessed 2013 Aug 3)."},{"key":"2019041210503855700_b58-0710279","unstructured":"ClinicalTrials.gov. Omacetaxine for consolidation and maintenance in patients age 60 and older with AML in first remission: a pilot study. www.clinicaltrials.gov\/ct2\/show\/NCT01873495 (accessed 2013 Aug 3)."}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/71\/4\/279\/28372203\/ajhp0279.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T18:25:14Z","timestamp":1746123914000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/71\/4\/279\/5111151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,15]]},"references-count":58,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,2,15]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp130506","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"type":"print","value":"1079-2082"},{"type":"electronic","value":"1535-2900"}],"subject":[],"published-other":{"date-parts":[[2014,2,15]]},"published":{"date-parts":[[2014,2,15]]}}}